ArticleGland surgery2025
Multimodal ultrasound to predict central cervical lymph node metastasis in clinically lymph node-negative differentiated thyroid carcinomas: a two-center retrospective study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of thyroid cancer has been on the rise in recent decades. The preoperative diagnosis of central cervical lymph node metastasis (CCLNM) has been found to be associated with thyroid cancer recurrence and patient prognosis, as well as impacting surgical technique and scope decision. Therefore, it is imperative to have a precise preoperative assessment of CCLNM. Therefore, we developed a reliable predictive model which incorporates preoperative clinical data and multimodal ultrasound (US) features to accurately predict CCLNM in clinically lymph node-negative (cN0) T1/T2 differentiated thyroid carcinoma (DTC) patients. Methods: Patients diagnosed with DTC confirmed through pathological results between July 2023 and February 2025 were included in the retrospective study. The 613 patients were divided into the training cohort (n=357, from Shanghai General Hospital), internal validation cohort (n=153, from Shanghai General Hospital), and external validation cohort (n=103, from Xuzhou Centeral Hospital). Univariate and multivariable logistic regression analyses were used for assessing multimodal US variables associated with CCLNM, and a predictive model was constructed from the multivariable analysis. Predictive performance was assessed with the receiving operating characteristic (ROC) curve and was further evaluated in the internal and external validation datasets. Results: Patient age, tumor size, echogenicity, discontinuous capsule enhancement (DCE), and strain rate ratio (SRR) were found to be independently associated with CCLNM. The multimodal US model showed optimal diagnostic performance [area under the receiver operating characteristic curve (AUC), 0.84; 95% confidence interval (CI): 0.80, 0.88] in predicting CCLNM, and demonstrated good discrimination in both the internal (AUC, 0.81; 95% CI: 0.75, 0.88) and external validation cohorts (AUC, 0.80; 95% CI: 071, 0.87). Conclusions: Our proposed predictive model based on preoperative clinical and multimodal US parameters carries the potential to predict CCLNM in cN0 DTCs, and may assist in minimizing the risk of unnecessary prophylactic central lymph node dissection (PCLND) among such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.